» Articles » PMID: 39845975

Diagnostic Accuracy of -specific Triple-color FluoroSpot Assay in Differentiating Tuberculosis Infection Status in Febrile Patients with Suspected Tuberculosis

Overview
Journal Front Immunol
Date 2025 Jan 23
PMID 39845975
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study aims to evaluate the diagnostic accuracy of a (MTB)-specific triple-color FluoroSpot assay (IFN-γ/IL-2/TNF-α) in the differentiation of tuberculosis (TB) infection status in febrile patients.

Method: Febrile patients with suspected active TB (ATB) were consecutively enrolled. The frequencies and proportions of MTB-specific T cells secreting IFN-γ, IL-2, and TNF-α were detected at the single-cell level by triple-color FluoroSpot assay. The diagnostic index was fitted with a binary logistic regression model, and the diagnostic accuracy was evaluated according to the receiver operating characteristic (ROC) curve. The sensitivity, specificity, predictive values (PV), and likelihood ratios (LR) were calculated.

Result: A total of 210 febrile patients were enrolled, 53 patients were diagnosed with ATB (28 pathogen-confirmed vs. 25 clinically diagnosed) and 157 patients were non-ATB (84 with latent tuberculosis infection (LTBI) vs. 73 uninfected with MTB). Additionally, 30 pathogen-confirmed ATB patients were assembled. When diagnosing ATB, the area under the ROC curve (AUROC) of the MTB-specific triple-color FluoroSpot assay was significantly better than that of T-SPOT.TB (0.882 vs. 0.811, = 0.017). With the fitted diagnostic index at a cutoff value of 0.378, the sensitivity, specificity, LR+, and LR- were 74.7%, 93.0%, 10.66, and 0.27, respectively. When differentiating ATB from LTBI, the AUROC of the FluoroSpot assay and T-SPOT.TB was 0.878 and 0.692, respectively ( < 0.001). With a diagnostic index of 0.413, the sensitivity, specificity, LR+, and LR were 77.1%, 85.7%, 5.40, and 0.27, respectively.

Conclusion: The MTB-specific triple-color FluoroSpot (IFN-γ/IL-2/TNF-α) might be helpful for the differentiation of TB infection status in febrile patients.

References
1.
Liang Y, Zhang X, Xiao L, Bai X, Wang X, Yang Y . Immunogenicity and therapeutic effects of pVAX1- rv1419 DNA from Mycobacterium tuberculosis. Curr Gene Ther. 2016; . View

2.
Holgersson J, Ceric A, Sethi N, Nielsen N, Jakobsen J . Fever therapy in febrile adults: systematic review with meta-analyses and trial sequential analyses. BMJ. 2022; 378:e069620. PMC: 9274300. DOI: 10.1136/bmj-2021-069620. View

3.
Sia J, Georgieva M, Rengarajan J . Innate Immune Defenses in Human Tuberculosis: An Overview of the Interactions between Mycobacterium tuberculosis and Innate Immune Cells. J Immunol Res. 2015; 2015:747543. PMC: 4516846. DOI: 10.1155/2015/747543. View

4.
Li Y, Yang Z, Ge Q, Zhang Y, Gao M, Liu X . Specific Cytokines Analysis Incorporating Latency-Associated Antigens Differentiates Infection Status: An Exploratory Study. Infect Drug Resist. 2024; 17:3385-3393. PMC: 11317045. DOI: 10.2147/IDR.S470963. View

5.
Pang Y, An J, Shu W, Huo F, Chu N, Gao M . Epidemiology of Extrapulmonary Tuberculosis among Inpatients, China, 2008-2017. Emerg Infect Dis. 2019; 25(3):457-464. PMC: 6390737. DOI: 10.3201/eid2503.180572. View